NCT Number: NCT02135211
Healthy Directions After Lung Surgery Pilot
The objective of this proposal is to test the feasibility and acceptability of a lifestyle risk reduction intervention for patients with lung cancer receiving surgical treatment. This study will provide the preliminary data needed to conduct a larger randomized controlled trial that tests an innovative, multidisciplinary intervention that has the potential to transform the standard of care for patients receiving surgical treatment for lung cancer.
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Brigham & Woman's Hospital, Boston, Massachusetts, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patient Inclusion Criteria:
- > 21 years of age
- English speaking
- MD approval to participate in study
- Meets one of the inclusions below:
- 1. a histological diagnosis of NSCLC undergoing potentially curative treatment
- 2. OR those undergoing surgical procedures for lung cancer (includes patients undergoing diagnostic testing or those presenting with lung nodules
- 3.OR patients who have had a surgical procedure for lung cancer within the last six months.
- May invite a buddy to join study with them defined as a friend, partner, adult child or sibling
Buddy Inclusion Criteria:
- ≥ 21 years of age,
- English speaking, who is invited by the subject to join as a support person (e.g., friend, partner, adult child or sibling)
Treatment and study plan
Primary outcomes
-
Feasibility and acceptability
Time frame: at end of study (4 months post intervention)
The primary outcome measures to establish feasibility and acceptability of the intervention for this study are enrollment rates.
-
Feasibility and acceptability
Time frame: at end of study (4 months post intervention)
The primary outcome measures to establish feasibility and acceptability patient's use of intervention materials
-
Feasibility and acceptability
Time frame: at end of study (4 months post intervention
The primary outcome measures to establish feasibility and acceptability of the completion of self-monitoring
-
Feasibility and acceptability
Time frame: at end of study (4 months post intervention)
The primary outcome measures to establish feasibility and acceptability of the intervention for this study completion of nurse-patient contacts.
Secondary outcomes
-
Interest for this study
Time frame: baseline, 1 month, & 4 month
The secondary outcome measures of interest for this study are lifestyle risk reduction and Health Related-Quality of Life.
-
Interest for this study
Time frame: baseline, 1 month, & 4 month
The secondary outcome measures of interest for this study is an interview to evaluate the intervention will be conducted with the participant and the partner at the conclusion of the study.
Sponsors and collaborators
Lead sponsor
Dana-Farber Cancer Institute
Other
Collaborators
- Brigham and Women's Hospital
- University of Massachusetts, Boston
Registry information
Official study title
Feasibility and Acceptability of a Lifestyle Intervention for Patients Receiving Surgical Treatment for Lung Surgery
Important dates
- Study start
- 2012
- Primary completion
- 2014
- Study completion
- 2015
- First posted
- May 9, 2014
- Registry last updated
- Jul 2, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
NCT00553254
Bronchial Neoplasms, Carcinoma, Bronchogenic
Seoul, South Korea
View Trial DetailsDocetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
NCT01671332
Bronchial Neoplasms, Carcinoma, Bronchogenic
Madison, Wisconsin, United States
View Trial DetailsVorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
NCT00798720
Bronchial Neoplasms, Carcinoma, Bronchogenic
View Trial DetailsIntra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
NCT00954278
Bronchial Neoplasms, Carcinoma, Bronchogenic
Madison, Wisconsin, United States
View Trial Details